Insider Buying: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Insider Acquires 2,836 Shares of Stock
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) insider Barbara White purchased 2,836 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $7.00 per share, for a total transaction of $19,852.00. Following the completion of the purchase, the insider now directly owns 174,050 shares of the company’s stock, valued at $1,218,350. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) traded down $0.35 during mid-day trading on Monday, hitting $6.90. The stock had a trading volume of 731,998 shares, compared to its average volume of 811,531. Corbus Pharmaceuticals Holdings, Inc. has a 52 week low of $5.30 and a 52 week high of $10.50.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. The company had revenue of $0.80 million for the quarter. sell-side analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/11/13/insider-buying-corbus-pharmaceuticals-holdings-inc-crbp-insider-acquires-2836-shares-of-stock.html.
Several equities analysts recently issued reports on CRBP shares. Cantor Fitzgerald set a $24.00 price target on Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research note on Monday, July 17th. BidaskClub lowered Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Noble Financial restated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Wednesday, August 9th. Finally, ValuEngine lowered Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $20.75.
Corbus Pharmaceuticals Holdings Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.